Search

Showing total 111 results
Start Over Topic urine Journal analytical and bioanalytical chemistry Publisher springer berlin heidelberg
111 results

2. Detection of ovarian cancer (± neo-adjuvant chemotherapy effects) via ATR-FTIR spectroscopy: comparative analysis of blood and urine biofluids in a large patient cohort

Author

Pierre L. Martin-Hirsch, Francis Martin, Camilo L. M. Morais, Nicholas J Wood, Brice Rodriguez, and Panagiotis Giamougiannis

Subjects
Oncology, medicine.medical_specialty, medicine.medical_treatment, ATR-FTIR spectroscopy, Atr ftir spectroscopy, Urine, 01 natural sciences, Biochemistry, Analytical Chemistry, Liquid biopsies, Cohort Studies, 03 medical and health sciences, Blood serum, Ovarian cancer, Internal medicine, Blood plasma, Biofluids, Spectroscopy, Fourier Transform Infrared, medicine, Biomarkers, Tumor, Chemotherapy, Humans, Neo adjuvant chemotherapy, F180, Spectroscopy, 030304 developmental biology, Ovarian Neoplasms, 0303 health sciences, business.industry, 010401 analytical chemistry, Membrane Proteins, medicine.disease, 0104 chemical sciences, Chemotherapy, Adjuvant, CA-125 Antigen, Case-Control Studies, Cohort, Female, business, Research Paper
Abstract

Graphical abstract Ovarian cancer remains the most lethal gynaecological malignancy, as its timely detection at early stages remains elusive. Attenuated total reflection Fourier-transform infrared (ATR-FTIR) spectroscopy of biofluids has been previously applied in pilot studies for ovarian cancer diagnosis, with promising results. Herein, these initial findings were further investigated by application of ATR-FTIR spectroscopy in a large patient cohort. Spectra were obtained by measurements of blood plasma and serum, as well as urine, from 116 patients with ovarian cancer and 307 patients with benign gynaecological conditions. A preliminary chemometric analysis revealed significant spectral differences in ovarian cancer patients without previous chemotherapy (n = 71) and those who had received neo-adjuvant chemotherapy—NACT (n = 45), so these groups were compared separately with benign controls. Classification algorithms with blind predictive model validation demonstrated that serum was the best biofluid, achieving 76% sensitivity and 98% specificity for ovarian cancer detection, whereas urine exhibited poor performance. A drop in sensitivities for the NACT ovarian cancer group in plasma and serum indicates the potential of ATR-FTIR spectroscopy to identify chemotherapy-related spectral changes. Comparisons of regression coefficient plots for identification of biomarkers suggest that glycoproteins (such as CA125) are the main classifiers for ovarian cancer detection and responsible for smaller differences in spectra between NACT patients and benign controls. This study confirms the capacity of biofluids’ ATR-FTIR spectroscopy (mainly blood serum) to diagnose ovarian cancer with high accuracy and demonstrates its potential in monitoring response to chemotherapy, which is reported for the first time. ATR-FTIR spectroscopy of blood serum achieves good segregation of ovarian cancers from benign controls, with attenuation of differences following neo-adjuvant chemotherapy. Supplementary Information The online version contains supplementary material available at 10.1007/s00216-021-03472-8.

Published
2021